Consistently, subgroup analysis also confirmed that patients with preserved liver function (Child–Pugh class A), dominant tumor size <6 cm, low AFP (<400 ng/ml), no history of HBV and HCV infection, are men, and aged >58 years could benefit from this combination therapy (Table 5). The gene discussed is AFP; the disease is neoplasm.